332 related articles for article (PubMed ID: 25175458)
1. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
[TBL] [Abstract][Full Text] [Related]
2. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
Antonelli T; Fuxe K; Agnati L; Mazzoni E; Tanganelli S; Tomasini MC; Ferraro L
J Neurol Sci; 2006 Oct; 248(1-2):16-22. PubMed ID: 16765381
[TBL] [Abstract][Full Text] [Related]
3. Understanding the role of heteroreceptor complexes in the central nervous system.
Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S
Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022
[TBL] [Abstract][Full Text] [Related]
4. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.
Fuxe K; Agnati LF; Jacobsen K; Hillion J; Canals M; Torvinen M; Tinner-Staines B; Staines W; Rosin D; Terasmaa A; Popoli P; Leo G; Vergoni V; Lluis C; Ciruela F; Franco R; Ferré S
Neurology; 2003 Dec; 61(11 Suppl 6):S19-23. PubMed ID: 14663004
[TBL] [Abstract][Full Text] [Related]
5. Allosteric Interactions between Adenosine A
Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
[TBL] [Abstract][Full Text] [Related]
6. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
7. A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence.
Pelassa S; Guidolin D; Venturini A; Averna M; Frumento G; Campanini L; Bernardi R; Cortelli P; Buonaura GC; Maura G; Agnati LF; Cervetto C; Marcoli M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109007
[TBL] [Abstract][Full Text] [Related]
8. Behavioral control by striatal adenosine A
Taura J; Valle-León M; Sahlholm K; Watanabe M; Van Craenenbroeck K; Fernández-Dueñas V; Ferré S; Ciruela F
Genes Brain Behav; 2018 Apr; 17(4):e12432. PubMed ID: 29053217
[TBL] [Abstract][Full Text] [Related]
9. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
[TBL] [Abstract][Full Text] [Related]
10. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
[TBL] [Abstract][Full Text] [Related]
11. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
12. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
13. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
Mori A; Shindou T
Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
[TBL] [Abstract][Full Text] [Related]
14. Purinergic signaling in Parkinson's disease. Relevance for treatment.
Navarro G; Borroto-Escuela DO; Fuxe K; Franco R
Neuropharmacology; 2016 May; 104():161-8. PubMed ID: 26211977
[TBL] [Abstract][Full Text] [Related]
15. Functional role of striatal A2A, D2, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission.
Beggiato S; Tomasini MC; Borelli AC; Borroto-Escuela DO; Fuxe K; Antonelli T; Tanganelli S; Ferraro L
J Neurochem; 2016 Jul; 138(2):254-64. PubMed ID: 27127992
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers.
Soriano A; Ventura R; Molero A; Hoen R; Casadó V; Cortés A; Fanelli F; Albericio F; Lluís C; Franco R; Royo M
J Med Chem; 2009 Sep; 52(18):5590-602. PubMed ID: 19711895
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.
Fuxe K; Ferré S; Canals M; Torvinen M; Terasmaa A; Marcellino D; Goldberg SR; Staines W; Jacobsen KX; Lluis C; Woods AS; Agnati LF; Franco R
J Mol Neurosci; 2005; 26(2-3):209-20. PubMed ID: 16012194
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptors and basal ganglia physiology.
Schiffmann SN; Fisone G; Moresco R; Cunha RA; Ferré S
Prog Neurobiol; 2007 Dec; 83(5):277-92. PubMed ID: 17646043
[TBL] [Abstract][Full Text] [Related]
20. Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia.
Borroto-Escuela DO; Ferraro L; Narvaez M; Tanganelli S; Beggiato S; Liu F; Rivera A; Fuxe K
Cells; 2020 Apr; 9(5):. PubMed ID: 32349279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
